Complete Response to Pembrolizumab After Progression on Avelumab Maintenance in Metastatic Urothelial Carcinoma.
[INTRODUCTION] Avelumab maintenance after response to platinum chemotherapy improves outcomes in metastatic urothelial carcinoma.
APA
Ito F, Kobayashi K, et al. (2026). Complete Response to Pembrolizumab After Progression on Avelumab Maintenance in Metastatic Urothelial Carcinoma.. IJU case reports, 9(2), e70160. https://doi.org/10.1002/iju5.70160
MLA
Ito F, et al.. "Complete Response to Pembrolizumab After Progression on Avelumab Maintenance in Metastatic Urothelial Carcinoma.." IJU case reports, vol. 9, no. 2, 2026, pp. e70160.
PMID
41804323
Abstract
[INTRODUCTION] Avelumab maintenance after response to platinum chemotherapy improves outcomes in metastatic urothelial carcinoma. Progression during maintenance presents a therapeutic dilemma.
[CASE PRESENTATION] A 72-year-old man underwent radical cystectomy and left nephroureterectomy for high-grade urothelial carcinoma. Two and a half years later, a solitary pelvic nodal recurrence achieved complete response to gemcitabine-cisplatin, after which avelumab maintenance was started. After 16 cycles, the same node regrew, indicating progression. Pembrolizumab was initiated and induced a second complete response after four cycles. He remains recurrence-free for three years without immune-related adverse events.
[CONCLUSION] Durable remission with pembrolizumab following progression on avelumab suggests that switching from PD-L1 to PD-1 blockade can overcome resistance in selected patients; prospective studies and biomarker strategies, including PD-L2 assessment, are warranted and may guide individualized rechallenge strategies.
[CASE PRESENTATION] A 72-year-old man underwent radical cystectomy and left nephroureterectomy for high-grade urothelial carcinoma. Two and a half years later, a solitary pelvic nodal recurrence achieved complete response to gemcitabine-cisplatin, after which avelumab maintenance was started. After 16 cycles, the same node regrew, indicating progression. Pembrolizumab was initiated and induced a second complete response after four cycles. He remains recurrence-free for three years without immune-related adverse events.
[CONCLUSION] Durable remission with pembrolizumab following progression on avelumab suggests that switching from PD-L1 to PD-1 blockade can overcome resistance in selected patients; prospective studies and biomarker strategies, including PD-L2 assessment, are warranted and may guide individualized rechallenge strategies.
같은 제1저자의 인용 많은 논문 (4)
- Very Late Recurrence of Clear Cell Renal Cell Carcinoma With Pancreatic and Hepatic Metastases Showing Durable Response to Dual Checkpoint Blockade.
- Fatal Interstitial Pneumonitis During Combined Degarelix, Darolutamide, and Docetaxel Therapy for Metastatic Prostate Cancer.
- Durable complete radiographic and biochemical response to olaparib in BRCA2-mutated metastatic castration-resistant prostate cancer: a long-term responder case.
- Unexpected Fatal Pneumocystis Jirovecii Pneumonia During Triplet Therapy for Hormone-Sensitive Prostate Cancer.